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Neurobiology SelectNeurodegenerative diseases cause profound suffering, and patients are often faced with few therapeutic options.
Elucidating new therapeutic avenues requires a better understanding of the aberrant molecular mechanisms that result
in death of select neuronal populations. Recent studies use classic cell and molecular biology assays and the latest
sequencing technologies to investigate the molecular pathogenesis of different neurodegenerative diseases from the
DNA level to the whole organism.Wild-type (left) and HD (right) mouse cells
containing autophagosomes with and
without cytosolic cargo, respectively. Photo
courtesy of A. Cuervo.Hunting Down a Defect in Autophagy
Huntington’s disease (HD) is a hereditary neurodegenerative disorder in which aberrant
expansion of glutamine repeats in the protein huntingtin results in a mutant protein that is
prone to forming aggregates. Although mutant huntingtin is cleared by the autophagy
pathway, the aggregates accumulate, eventually killing striatal neurons in the brain. Mar-
tinez-Vicente et al. (2010) now shed fresh light on the part played by a type of autophagy
called macroautophagy in HD pathogenesis. During macroautophagy, regions of cyto-
plasm including organelles are engulfed into large double-membraned vesicles called
autophagosomes, which then fuse with lysosomes, resulting in degradation of the auto-
phagosomes’ cytosolic cargo. The authors first looked at embryonic fibroblasts from
wild-type mice with normal 18-glutamine-repeat huntingtin and HD mice with mutant
111-glutamine-repeat huntingtin. Although macroautophagy was activated in both
cell types in response to serum removal, there was markedly less protein degradation in HD cells compared with wild-type cells. There
was also decreased protein degradation after macroautophagy activation in lymphoblasts from HD patients and in striatal neurons
from another HD mouse model in which exon 1 of mutant human huntingtin is overexpressed. Using biochemical and morphological
assays, the authors then showed that decreased protein degradation in HD cells was not due to a defect in macroautophagy activation
or lysosome activity, or decreased expression of autophagy-associated proteins, including Atg4 and beclin-1. But when they
compared normal and HD mouse and human cells by electron microscopy, they realized that although autophagosomes formed prop-
erly in HD cells, they seemed to be ‘‘empty,’’ lacking a normal cytosolic cargo of organelles and polyubiquitinated proteins. The authors
propose that a decreased ability to sequester cytosolic components in HD cells could slow degradation of unwanted organelles and
proteins contributing to neuronal toxicity in HD. But how could mutant huntingtin be involved in this macroautophagy defect? The
authors discovered that mutant huntingtin interacted abnormally with a key cargo recognition molecule (p62), suggesting that it
may disrupt cargo recognition by autophagosomes. It is also possible that mutant huntingtin binds directly to cargo proteins, prevent-
ing their engulfment by autophagosomes, or that wild-type huntingtin has a direct function in some aspect of macroautophagy that the
mutant protein cannot perform.
M. Martinez-Vicente et al. (2010). Nat. Neurosci. 13, 567–576.
Memories Are Made of This
A drug called SAHA that boosts the acetylation of histones may prove useful not only for treating patients with Huntington’s disease but
also for ameliorating age-related cognitive decline, according to new work by Peleg et al. (2010). These authors set out to examine the
effects of histone modifications (specifically histone acetylation) and chromatin plasticity on long-term memory formation in young and
old mice. First, the authors investigated how young (3 month) and old (16 month) mice fared in two classic tests requiring hippocampal-
dependent associative learning (fear conditioning) and spatial memory formation (water maze). The 16-month-old mice showed
a slower freeze response and took longer to reach the swim platform in the fear-conditioning test and Morris water maze swim
test, respectively, compared to their 3-month-old counterparts. Next, the authors analyzed histone modifications and gene expres-
sion profiles in the hippocampal tissue of young and old mice 1 hr after fear-conditioning training. Young mice showed acetylation of
lysine 12 on histone H4 (H4K12) in the hippocampus, which correlated with altered expression of 1532 genes specifically associated
with memory formation, whereas old mice showed neither H4K12 acetylation or altered gene expression. The authors then infused the
histone deacetylase (HDAC) inhibitor SAHA into the hippocampus of old mice to boost H4K12 acetylation and to see if this improved
memory formation. There was an increase in both H4K12 acetylation and gene expression in the hippocampus of SAHA-treated old
mice 1 hr after training, which was associated with an improved freeze response during the fear-conditioning test. HDAC inhibitors that
boosted histone acetylation modifications other than H4K12 failed to rescue gene expression and memory formation in the old mice.
Although these findings suggest that SAHA may be useful for treating age-related memory loss in humans, a better therapeutic
approach may be to prevent the age-related decline in H4K12 acetylation in hippocampal neurons in the first place.
S. Peleg et al. (2010). Science 328, 753–756Keeping an Eye Out for ALS Mutations
The protein huntingtin mutated in Huntington’s disease interacts with many proteins, one of which, called optineurin, has itself been
implicated in a form of glaucoma. Optineurin is a coiled-coil protein that associates not only with huntingtin but also with ubiquitin, the
motor protein myosin VI, and the ubiquitin receptor-interacting protein and is involved in membrane trafficking and exocytosis. A new
study by Maruyama et al. (2010) implicates mutations in optineurin in a neurodegenerative disease called amyotrophic lateral scle-
rosis (ALS), which is characterized by degeneration of motor neurons. Although mutations in genes such as SOD-1 have been iden-
tified in a small number of ALS patients, the mechanisms underlying the death of motor neurons are still unclear. Using a genome-wideCell 141, May 28, 2010 ª2010 Elsevier Inc. 735
scan of sequence variations called single-nucleotide polymorphisms (SNPs) in Japanese ALS patients with a familial (inherited) or
sporadic (noninherited) form of the disease, Maruyama and colleagues identify three types of mutations in the gene encoding opti-
neurin that are associated with ALS. The Q398X nonsense mutation and deletion of exon 5 in the optineurin gene cause a premature
block in translation resulting in a truncated protein that cannot bind to its targets. Meanwhile, the E478G missense mutation results in
substitution of a highly conserved glutamic acid in the ubiquitin-binding domain of optineurin. Optineurin is not only involved in traf-
ficking but also competes with NEMO (NF-kB essential molecule) for binding to the ubiquitin receptor-interacting protein resulting in
a block in the activation of the master transcription factor NF-kB. When the authors transfected neuroblastoma cells with wild-type or
mutant optineurin, they discovered that the nonsense and missense mutations resulted in an optineurin protein that was unable to
switch off NF-kB activation; the missense mutation also resulted in mislocalization of optineurin. Intriguingly, the motor neurons of
an ALS patient with the E478G mutation had cytoplasmic inclusions containing mutant optineurin. Surprisingly, ALS patients with
SOD-1 mutations and individuals with sporadic ALS also had motor neuron inclusions containing optineurin, suggesting that opti-
neurin could be a general marker for ALS. The next step will be to elucidate how mutant optineurin contributes to the death of motor
neurons, the part played by cytoplasmic inclusions, and how defective protein trafficking or aberrant NF-kB activation are involved.
H. Maruyama et al. (2010). Nature 465, 223–260.Complete sequencing of identi-
cal twin genomes provides new
insights into disease. Photo cour-
tesy of S.E. Baranzini.Sequencing the Differences between Identical Twins
Maruyama et al. conducted a genome-wide association study looking at SNPs to identify a new
gene involved in ALS; however, the next frontier is to sequence the entire genome of patients
and their families and to compare the full genome sequences directly to identify new disease genes.
This is the approach taken by Baranzini et al. (2010) ina tour-de-force study of a pair of monozygotic
(identical) twins, one with and one without (that is, discordant for) the neurological disease multiple
sclerosis (MS). This disease is characterized by loss of the protective myelin sheath surrounding
nerves as a result of autoimmune attack by CD4+ T lymphocytes. Using CD4+ T lymphocytes
from a twin pair discordant for MS, the investigators sequenced their complete genomes seeking
genetic differences that might explain why one twin suffered from the disease and the other did not.
Surprisingly, the researchers came up empty-handed and were unable to find any differences in the
3.6 million SNPs, insertion-deletion polymorphisms, or copy number variations analyzed between
the two genomes. Using CD4+ T lymphocytes from three twin pairs discordant for MS, the authors
looked at both genome-wide mRNA expression (the transcriptome) and genome-wide variations in
cytosine methylation at CpG sites (the epigenome) between the sick and healthy twin of each pair.
Once again, they saw no differences in genome-wide gene expression and very few differences in
cytosine methylation (the few differences observed were not replicated across twin pairs). The
surprising results are important because they suggest that discordance for MS in monozygotic
twins has a new environmental trigger even though there is a strong inherited component to this disease (the healthy monozygotic
twin has a 25% chance of developing MS). Next, the researchers should analyze the complete genomes of more pairs of monozygotic
twins with and without MS and examine their neurons rather than lymphocytes.
S.E. Baranzini et al. (2010). Nature 464, 1351–1356.
Dampening Down Dopamine Signaling
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons in the nigrostriatal pathway
of the brain, resulting in motor abnormalities. A mainstay of treatment is L-dopa, which is broken down by neurons into the neurotrans-
mitter dopamine. Chronic L-dopa treatment, however, results in serious side effects, including involuntary movements (dyskinesias),
thus limiting the dose of L-dopa that can be given to PD patients. Ahmed et al. (2010), working in rat and primate models of PD, now
elucidate the pathway responsible for L-dopa-induced dyskinesias. The authors suspected that hypersensitivity of the D1 and D2
dopamine receptors to dopamine as a result of a reduced ability to downmodulate dopamine signaling could be the culprit. Like other
G protein-coupled receptors (GPCRs), the D1 and D2 receptors are desensitized to dopamine through phosphorylation by a GPCR
kinase (in this case GRK6), leading to their internalization and a decrease in dopamine signaling. GRK6 expression is reduced in
the striatum of animals with PD receiving L-dopa therapy. Thus, the investigators surmised that boosting GRK6 expression in animals
with PD might ameliorate hyperstimulation of D1 and D2 receptors such that the therapeutic benefits of L-dopa could be retained while
the L-dopa-induced dyskinesias could be abolished. Overexpressing GRK6 in the brains of L-dopa-treated rats with PD (induced by 6-
OHDA, which selectively kills off dopaminergic neurons) reduced abnormal voluntary movements (equivalent to dyskinesias in human
PD patients). However, when GRK6 expression was blocked with RNA interference in the L-dopa-treated PD rats, abnormal involun-
tary movements increased. Next, the authors overexpressed GRK6 in the striatum of monkeys administered the drug MPTP to destroy
dopaminergic neurons and then treated therapeutically with L-dopa. Monkeys overexpressing GRK6 not only showed a reduction in
dyskinesias but also showed prolonged alleviation of parkinsonian symptoms even at reduced doses of L-dopa. These encouraging
results suggest that modulating dopamine signaling may benefit PD patients on chronic L-dopa therapy not only by preventing dyski-
netic side effects but also by reducing the dose of L-dopa required to alleviate the symptoms of PD.
M. R. Ahmed et al. (2010). Sci. Trans. Med. 2, 28ra28.
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